secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001193125-26-152045
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna dosed first participants in Phase 1 trial of SEP-479 oral PTH1R agonist for hypoparathyroidism
--------------------------------------------------------------------------------

- Phase 1 SAD/MAD trial evaluating safety, tolerability, PK/PD in up to 150 healthy volunteers.
- SEP-479 is a potent oral small molecule PTH1R agonist for hypoparathyroidism, a lifelong condition.
- Data from the trial expected in late 2026 or early 2027.
- CEO highlights potential as once-daily oral therapy, differentiating from daily injections or calcium supplements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526152045/0001193125-26-152045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526152045/d57504d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-152045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer